Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), TG Therapeutics (TGTX) and Vertex Pharmaceuticals (VRTX)
BofA Securities Maintains TG Therapeutics(TGTX.US) With Sell Rating, Maintains Target Price $11
TG Therapeutics First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
Sell Rating for TG Therapeutics Amidst Growth Concerns and Competitive Challenges
TD Cowen Maintains TG Therapeutics(TGTX.US) With Buy Rating, Maintains Target Price $50
Jefferies Maintains TG Therapeutics(TGTX.US) With Buy Rating, Maintains Target Price $46
Q1 2025 TG Therapeutics Inc Earnings Call
Top Gap Ups and Downs on Monday: BRK.A, BRK.B, BBVA and More
Why TG Therapeutics Stock Was Tumbling Today
TG Therapeutics Down Over 15%, on Track for Largest Percent Decrease Since August 2023 -- Data Talk
Crude Oil Falls Over 2%; ISM Services PMI Rises In April
TG Therapeutics Shares Fall After 1Q Earnings Miss
TG Therapeutics: Strong Financial Performance and Strategic Growth Justify Buy Rating
Earnings Call Summary | TG Therapeutics(TGTX.US) Q1 2025 Earnings Conference
These Are the Sectors Best Liked Within Defensive and Cyclicals Groups – Morgan Stanley
TG Therapeutics Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 EPS Results.
TG Therapeutics | 8-K: TG Therapeutics Reports First Quarter 2025 Financial Results and Raises BRIUMVI Full Year Revenue Guidance
Express News | TG Therapeutics Inc: Q2 2025 Briumvi U.S. Net Product Revenue Target of $135 Mln
TG Therapeutics GAAP EPS of $0.03 Misses by $0.14, Revenue of $120.86M Beats by $3M
Earnings Flash (TGTX) TG Therapeutics Reports Q1 Revenue $120.9M, Vs. FactSet Est of $117.9M